{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:29:35Z","timestamp":1740162575189,"version":"3.37.3"},"reference-count":29,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1136\/bmjopen-2016-014427","type":"journal-article","created":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T00:10:56Z","timestamp":1499127056000},"page":"e014427","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study"],"prefix":"10.1136","volume":"7","author":[{"given":"Masato","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoko","family":"Uno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,7,2]]},"reference":[{"key":"key-10.1136\/bmjopen-2016-014427-1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.5551\/jat.6866","article-title":"Lifestyle and cardiovascular disease in Japan","volume":"18","author":"Iso","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"key-10.1136\/bmjopen-2016-014427-2","first-page":"256","article-title":"Jeremiah Metzger lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?","volume":"122","author":"Gotto","year":"2011","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"key-10.1136\/bmjopen-2016-014427-3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"key-10.1136\/bmjopen-2016-014427-4","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"key-10.1136\/bmjopen-2016-014427-5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"key-10.1136\/bmjopen-2016-014427-6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"key-10.1136\/bmjopen-2016-014427-7","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"2016","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"key-10.1136\/bmjopen-2016-014427-8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/bmjopen-2016-014427-9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bmjopen-2016-014427-10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"key-10.1136\/bmjopen-2016-014427-11","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"2014","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"key-10.1136\/bmjopen-2016-014427-12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"key-10.1136\/bmjopen-2016-014427-13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/01.CIR.0000140261.58966.A4","article-title":"Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study","volume":"110","author":"Okazaki","year":"2004","journal-title":"Circulation"},{"key":"key-10.1136\/bmjopen-2016-014427-14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.atherosclerosis.2009.12.001","article-title":"Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study","volume":"210","author":"Dohi","year":"2010","journal-title":"Atherosclerosis"},{"key":"key-10.1136\/bmjopen-2016-014427-15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"key-10.1136\/bmjopen-2016-014427-16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","article-title":"Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study)","volume":"54","author":"Hiro","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/bmjopen-2016-014427-17","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1253\/circj.CJ-09-0358","article-title":"Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)","volume":"73","author":"Takayama","year":"2009","journal-title":"Circ J"},{"key":"key-10.1136\/bmjopen-2016-014427-18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcme.2014.03.001","article-title":"Effect of combination of ezetimibe and a statin on coronary plaque regression in patients with acute coronary syndrome","volume":"3","author":"Nakajima","year":"2014","journal-title":"IJC Metab Endocr"},{"key":"key-10.1136\/bmjopen-2016-014427-19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual\u00a0lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the Multicenter Randomized Controlled PRECISE-IVUS Trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key-10.1136\/bmjopen-2016-014427-20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.5551\/jat.14159","article-title":"Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"key-10.1136\/bmjopen-2016-014427-21","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"key-10.1136\/bmjopen-2016-014427-22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"key":"key-10.1136\/bmjopen-2016-014427-23","first-page":"1187","article-title":"Investigation on risk factors in patients with high LDL cholesterol and HDL cholesterol and treatment on hyperlipidaemia in Japan\u2014Lipid Management Program (LiMAP) in Japan\u2014[in Japanese]","volume":"35","author":"Tada","year":"2005","journal-title":"J Adult Dis"},{"key":"key-10.1136\/bmjopen-2016-014427-24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.116.023007","article-title":"Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes","volume":"134","author":"Nanchen","year":"2016","journal-title":"Circulation"},{"key":"key-10.1136\/bmjopen-2016-014427-25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/fca.13.107","article-title":"Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and phase I and II clinical trial results of a PCSK9 monoclonal antibody","volume":"10","author":"Roth","year":"2014","journal-title":"Future Cardiol"},{"key":"key-10.1136\/bmjopen-2016-014427-26","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"key-10.1136\/bmjopen-2016-014427-27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","article-title":"PCSK9 and lipid lowering drugs","volume":"437","author":"Guo","year":"2014","journal-title":"Clinica Chimica Acta"},{"key":"key-10.1136\/bmjopen-2016-014427-28","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","article-title":"Third universal definition of myocardial infarction","volume":"33","author":"Thygesen","year":"2012","journal-title":"Eur Heart J"},{"key":"key-10.1136\/bmjopen-2016-014427-29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10557-010-6223-2","article-title":"The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: rationale and design of a 2-year study in patients initially hospitalised with acute coronary syndrome in Japan","volume":"24","author":"Miyauchi","year":"2010","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-014427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T03:02:20Z","timestamp":1601089340000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-014427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,7,2]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1136\/bmjopen-2016-014427"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-014427","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}